2550818
doi
10.5281/zenodo.2550818
oai:zenodo.org:2550818
Systematic evaluation of the effects of metformin on the mTOR signalling pathway in the treatment of spinal cord injury
Yasin Emre Kaya
Assist. Prof. M.D.; Abant Izzet Baysal University School of Medicine, Department of Orthopaedic and Traumatology, 14030, Bolu, Turkey
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Metformin; mTOR ignalling pathway, rapamycin; spinal cord injury, sirolimus
<p><strong>Metformin is one of the safest drugs used to control blood sugar in diabetes. This drug is being investigated by orthopedists as well as by neurosurgeons as it may increase the locomotor recovery after spinal cord injury (SCI). In the present study, the aim was to evaluate a promising pharmacological agent, metformin, which is known to be used in SCI treatment by acting over the mammalian target of rapamycin (mTOR) and some other signaling pathway. Relevant clinical trials were included in the study following electronic database scan. Preclinical and cellular studies have demonstrated that metformin may have antitumoral properties, regulate inflammation, and therefore play a role in the tumor microenvironment, or that it has a therapeutic effect in SCI by acting over mTOR pathway. However, Level of I clinical trials should be performed to determine the effectiveness of metformin in SCI, a serious pathology.</strong></p>
Zenodo
2019-01-27
info:eu-repo/semantics/article
2550817
1579541487.497558
161093
md5:a5d87a0c1cebc1ef2e598c5a301db164
https://zenodo.org/records/2550818/files/Kaya pdf.docx
public
10.5281/zenodo.2550817
isVersionOf
doi